TrialFrontiers in immunology2020

Selection of a Clinical Lead TCR Targeting Alpha-Fetoprotein-Positive Liver Cancer Based on a Balance of Risk and Benefit.

Xiaobing Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.